Sustained Release Formulation for Localized BPH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Benign Prostatic Hyperplasia (BPH) are either invasive, require frequent administration due to drug diffusion, or cause adverse effects such as urinary and sexual dysfunction, necessitating a more effective and less invasive method for sustained relief of lower urinary tract symptoms.
Innovation Solution
A needle syringe delivery system for a sustained release formulation (SRF) that uses a composition comprising a drug and polymer carrier, allowing for precise, controlled delivery of low unit volumes to the prostate, minimizing uncontrolled drug diffusion and providing prolonged efficacy with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral medications are used to treat BPH, then lower urinary tract symptoms can be relieved, but the treatment requires daily dosing for patient compliance and carries side effects such as ejaculation changes, erectile dysfunction, and decreased libido
Solution Approach 1:
The treatment is segmented into multiple localized injection sites within the prostate gland, allowing the drug to be delivered directly to the target tissue in divided portions. This localized approach achieves therapeutic efficacy while minimizing systemic exposure and associated side effects.
Solution Approach 2:
The invention applies local quality by delivering the drug directly to the prostate tissue through targeted injections rather than systemic administration. This creates a high drug concentration at the treatment site while maintaining low systemic levels, thereby achieving symptom relief without the sexual dysfunction side effects associated with oral medications.
2Reliability
If traditional drug delivery methods are used, then drug can be administered to the prostate, but uncontrolled drug diffusion occurs requiring frequent administration
Solution Approach 1:
The invention employs a sustained-release formulation that is prepared in advance and delivered via localized injection. The drug is encapsulated or bound in a matrix that controls its release over time, providing prolonged therapeutic effect from a single administration and eliminating the need for frequent re-dosing.
Solution Approach 2:
The invention changes the physical and chemical parameters of the drug delivery system by using a sustained-release formulation with controlled release kinetics. This modifies the drug's release profile from rapid diffusion to controlled, prolonged release, thereby extending the effective treatment duration and reducing administration frequency.
3Reliability
If invasive surgical procedures are used to treat BPH, then significant symptom relief can be achieved, but the procedures carry higher risk and require more recovery time
Solution Approach 1:
The invention extracts the essential therapeutic function from invasive surgical procedures by delivering the drug directly to the prostate tissue through perineal injections. This eliminates the need for transurethral resection or other invasive surgeries, achieving comparable symptom relief with minimal invasion and faster recovery.
Solution Approach 2:
The invention introduces a drug delivery system as an intermediary between the patient and the prostate tissue. Instead of mechanically removing tissue through surgery, the drug acts as a mediator to shrink the prostate and relieve symptoms, thereby avoiding the risks and recovery time associated with invasive procedures.
Data Source
AI summary
Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.